Weeks to hours.
University of Missouri researcher turns bedside questions into real‑world evidence in hours
- Zeenat Qureshi Stroke Institute
- Neurology & stroke
- Medeloop Analytics
- HealthVerity linked claims
Dr. Adnan Qureshi cut analysis turnaround from weeks to hours with Medeloop Analytics and HealthVerity data. He now runs studies himself, without waiting on a bioinformatics team.
Read the paper in Neurological Research (opens in a new tab)
With a shared informatics team
Weeks
Per round of results
With Medeloop Analytics
3–4 hours
Per round of results
Same day: see a patient, have an analysis by afternoon.
Every question waited on a shared informatics team.
The real-world datasets Dr. Qureshi needed sat outside his institute, so each study ran through the university's bioinformatics team. Someone had to manually specify every diagnosis and medication code by hand, and even small coding changes could add weeks.
Checking outputs against published literature took at least five rounds per study. The readmission datasets available to him also lacked ED visits and medication data, two things he needed to tell the full picture.
Five or more rounds of back-and-forth per study.
An interactive research agent on linked HealthVerity data.
Real-time analysis replaced the handoff
Dr. Qureshi now runs and refines analyses himself. When a question needs narrowing, the agent suggests how to reword it or adjust the codes. Tedious tasks like wrangling messy data happen inside the platform.
“Everything is in real time. It's an interactive platform.”
Linked data opened new study designs
HealthVerity data on Medeloop Analytics links pharmacy refills, ED visits, and readmissions, a linkage that used to require a massive dataset and dedicated hardware. “Before, it would not be something that I would be able to do on my own.”
His work on Medeloop spans two studies.
Recurrent stroke risk
Measured the four-year risk of a second stroke in patients with extracranial vertebral artery stenosis, and when those strokes occur. The findings shape how long and how aggressively to treat.
Antiplatelet adherence and harm
Followed a year of real-world antiplatelet use in stroke and TIA survivors. “The pharmacy refills will tell you how compliant they were,” he said, and the data shows who returned with bleeding complications.
Statistics ahead of the manuscript for the first time in 30 years.
Dr. Qureshi estimates the platform saves him months per study. “This is the first time the statistical part has overtaken the manuscript preparation,” he said.
Scale achieved
- Published in Neurological Research (opens in a new tab); second paper accepted in American Journal of Pharmacotherapy
- Pharmacy refills, ED visits, and readmissions analyzed together
- Multiple studies running in parallel
A new pace for research
“We are in a real-time environment now.”
Dr. Adnan Qureshi
Professor of Neurology, University of Missouri
About Dr. Qureshi
Professor of Neurology at the University of Missouri, Program Director of its Endovascular Surgical Neuroradiology program, and founder of the Zeenat Qureshi Stroke Institute.
Read the paper in Neurological Research (opens in a new tab)